

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Pharmaxis Ltd

ABN

75 082 811 630

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|--|
| 1 | +Class of +securities issued or to be issued | <ol style="list-style-type: none"> Unlisted Employee Options over Pharmaxis Ltd ordinary shares Fully paid ordinary shares |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | <ol style="list-style-type: none"> <u>Options</u>: 200,000 <u>Shares</u>: 30,000 |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | <p><u>Options</u>:</p> <p>200,000 options have been issued to the chief executive officer following shareholder approval at the Company's annual general meeting held on 21 October 2009:</p> <ul style="list-style-type: none"> Exercise Price: \$2.5498 (5 day VWAP of Pharmaxis shares at Board resolution date) Expiry: 22 June 2019 Vesting: 30 June 2012: 200,000 Vesting of options is to approval by the Remuneration and Nomination Committee after a review of the Company's performance in achieving key business objectives. |

Ordinary Shares:

30,000 fully paid ordinary shares issued to a non executive director following shareholder approval at the Company's annual general meeting held on 21 October 2009:

- The shares are not able to be traded and will not vest in Mr van den Broek for a period of 3 years from the date of his appointment as a director. The shares will not vest if Mr van den Broek ceases to be a director during this time.
- As long as Mr van den Broek remains a director of the Company, the shares may only be traded with the prior approval of the Board.

- 4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Options:

No. Shares issued upon exercise will rank equally with existing ordinary shares.

Shares:

The share rank equally with all other fully paid ordinary shares on issue.

- 5 Issue price or consideration

Options: Nil consideration. Exercise price of \$2.5498 per option.

Shares: Nil consideration. Value of Pharmaxis shares on date of issue was \$2.63 per share.

- 6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

Options issued to one executive director under the Pharmaxis employee option plan and the shares have been issued to one non executive director of Pharmaxis as approved at the Company's annual general meeting held on 21 October 2009.

+ See chapter 19 for defined terms.

7	Dates of entering +securities into uncertificated holdings or despatch of certificates	22 October 2009
---	--	-----------------

8	Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="787 357 1063 388">Number</th> <th data-bbox="1063 357 1336 388">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="787 388 1063 600">217,929,734</td> <td data-bbox="1063 388 1336 600">Fully paid ordinary shares</td> </tr> </tbody> </table>	Number	+Class	217,929,734	Fully paid ordinary shares
Number	+Class					
217,929,734	Fully paid ordinary shares					

Number	+Class
--------	--------

9	Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	1,220,000	Options expiring on various dates with an exercise price of \$0.125 (ASX Code PXSAM)
		4,006,000	Options expiring on various dates with an exercise price of \$0.3125 (ASX Code PXS AO)
		500,000	Options expiring 30 November 2013 with an exercise price of \$0.376 (ASX Code PXS AQ)
		15,000	Options expiring 3 June 2014 with an exercise price of \$0.426 (ASX Code PXS AU)
		225,000	Options expiring 1 February 2015 with an exercise price of \$0.8340 (ASX Code PXS AY)
		290,000	Options expiring 11 May 2015 with an exercise price of \$1.147 (ASX Code PXS AW)
		747,500	Options expiring 4 August 2015 with an exercise price of \$1.79 (ASX Code PXS AZ)
		30,000	Options expiring 17 October 2015 with an exercise price of \$2.772 (ASX Code PXS AA)

+ See chapter 19 for defined terms.

35,000	Options expiring 12 February 2016 with an exercise price of \$2.194 (ASX Code PXSAB)
87,500	Options expiring 31 May 2016 with an exercise price of \$2.034 (ASX Code PXSAC)
812,250	Options expiring 14 August 2016 with an exercise price of \$1.917 (ASX Code PXSAD)
42,500	Options expiring 19 September 2016 with an exercise price of \$1.8918 (ASX Code PXSAE)
32,500	Options expiring 13 December 2016 with an exercise price of \$3.0710 (ASX Code PXSAF)
150,000	Options expiring 15 March 2016 with an exercise price of \$2.0680 (ASX Code PXSAG)
157,500	Options expiring 17 June 2017 with an exercise price of \$3.3155 (ASX Code PXS AH)
1,549,000	Options expiring 9 August 2017 with an exercise price of \$3.33890 (ASX Code PXSAL)
150,000	Options expiring 9 August 2017 with an exercise price of \$3.33890 (ASX Code PXS AI)
200,000	Options expiring 14 November 2016 with an exercise price of \$3.32258 (ASX Code PXS AK)

Number	+Class
507,000	Options expiring 5 November 2017 with an exercise price of \$4.2900 (ASX Code PXSAT)
2,000	Options expiring 13 December 2017 with an exercise price of \$4.1373 (ASX Code PXS AJ)
16,000	Options expiring 7 February 2018 with an exercise price of \$3.2666 (ASX Code PXS AN)
14,000	Options expiring 10 April 2018 with an exercise price of \$2.1135 (ASX Code PXS AP)
53,500	Options expiring 22 June 2018 with an exercise price of \$1.5990 (ASX Code PXS AR)
1,296,750	Options expiring 11 August 2018 with an exercise price of \$1.5990 (ASX Code PXS AS)
200,000	Options expiring 22 June 2018 with an exercise price of \$1.5990 (ASX Code PXS AV)
200,000	Options expiring 11 August 2018 with an exercise price of \$1.8170 (ASX Code PXS AX)
152,500	Options expiring 22 October 2018 with an exercise price of \$1.6060 (ASX Code PXS AAA)

+ See chapter 19 for defined terms.

Number	+Class
50,000	Options expiring 10 December 2018 with an exercise price of \$1.1607 (ASX Code PXSAAB)
276,000	Options expiring 4 February 2019 with an exercise price of \$1.3380 (ASX Code PXSAAC)
5,000	Options expiring 22 April 2019 with an exercise price of \$1.9574 (ASX Code PXSAAD)
1,608,500	Options expiring 22 June 2019 with an exercise price of \$2.5498 (ASX Code PXSAAE)
200,000	Options expiring 22 June 2019 with an exercise price of \$2.5498 (ASX Code PXS___)
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)
	n/a

Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or non-renounceable?
- 13 Ratio in which the +securities will be offered
- 14 +Class of +securities to which the offer relates
- 15 +Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

+ See chapter 19 for defined terms.

- []
- 30 How do +security holders sell their entitlements *in full* through a broker? []
- 31 How do +security holders sell *part* of their entitlements through a broker and accept for the balance? []
- 32 How do +security holders dispose of their entitlements (except by sale through a broker)? []
- 33 +Despatch date []

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities
(tick one)
- (a) Securities described in Part 1
- (b) All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
 1 - 1,000
 1,001 - 5,000
 5,001 - 10,000
 10,001 - 100,000
 100,001 and over
- 37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which
+quotation is sought

--

39 Class of +securities for which
quotation is sought

--

40 Do the +securities rank equally in all
respects from the date of allotment
with an existing +class of quoted
+securities?

If the additional securities do not
rank equally, please state:

- the date from which they do
- the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
- the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment

--

41 Reason for request for quotation
now

Example: In the case of restricted securities, end of
restriction period

(if issued upon conversion of
another security, clearly identify that
other security)

--

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)		

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.

• If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: Date: .. 22 October 2009
(Company secretary)

Print name:David McGarvey.....
== == == == ==

+ See chapter 19 for defined terms.